GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Cognition Inc (OTCPK:ACOGF) » Definitions » Preferred Dividends

Alpha Cognition (Alpha Cognition) Preferred Dividends : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Cognition Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Alpha Cognition's preferred dividends for the three months ended in Mar. 2024 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


Alpha Cognition Preferred Dividends Historical Data

The historical data trend for Alpha Cognition's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Cognition Preferred Dividends Chart

Alpha Cognition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Preferred Dividends
- - - -

Alpha Cognition Quarterly Data
Jan20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alpha Cognition Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.


Alpha Cognition  (OTCPK:ACOGF) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Cognition (Alpha Cognition) Business Description

Traded in Other Exchanges
Address
301 - 1228 Hamilton Street, Vancouver, BC, CAN, V6B 6L2
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.